Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR
Rhinology Journal · 2026
DOI: 10.4193/rhin25.514 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rhinology Journal, 2026. Verfasst von T Bartosik und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Nasal Polyps, Omalizumab, Rhinosinusitis.
Abstract (Originalsprache)
Omalizumab is a recombinant DNA-derived humanized monoclonal antibody targeting free immunoglobulin E. In the omalizumab phase III studies for chronic rhinosinusitis with nasal polyp (CRSwNP), a clinically relevant reduction of the nasal polyp score (NPS) was observed leading to improved SinoNasal Outcome Test-22 (SNOT-22) (1). In the extension study, sustained or further improvement of symptoms and NPS reduction were observed up to 52 weeks (2). Real-world data is needed to establish effectiveness in uncontrolled severe CRSwNP (3), but so far, data on long-term omalizumab treatment is sparse (4,5).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria.
- Galenus Health (part of Cascador Health Group), Tielrode, Belgium.
- Department of Otorhinolaryngology, Universitatsklinikum Dusseldorf (UKD), Dusseldorf, Germany.
- Otorhinolaryngology Department, Ordens Klinikum Linz, Linz, Austria.
- Department of General ORL, Head and Neck Surgery, Medical University of Graz, Graz, Austria.
- Rhinology Unit, Otorhinolaryngology Department, Hospital Universitari de Bellvitge, Universitat de Barcelona, IDIBELL, Barcelona, Catalonia, Spain.
Zitieren
APA
Bartosik, T., Seys, S. F., de Kinderen, J., Wagenmann, M., Bruch, M., Andrianakis, A., Gonzalez-Compta, X., Hox, V., Pardo Muà Oz, L., Schneider, S., Bettio, G., Burian, M., Eckl-Dorna, J., Golet Fors, M., Marien, G., Morgenstern, C., Scheckenbach, K., Tomazic, P. V., Tu, A., …, & Isam Alobid Carlo Cavaliere Wytske Fokkens Peter W Hellings Claire Hopkins Adriana Izquierdo-Doming…, C. C. (2026). Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR. Rhinology Journal. https://doi.org/10.4193/rhin25.514
Vancouver
Bartosik T, Seys SF, de Kinderen J, Wagenmann M, Bruch M, Andrianakis A, et al. Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR. Rhinology Journal. 2026. doi:10.4193/rhin25.514
BibTeX
@article{Bartosik2026,
author = {Bartosik, T and Seys, S F and de Kinderen, J and Wagenmann, M and Bruch, M and Andrianakis, A and Gonzalez-Compta, X and Hox, V and Pardo Muà Oz, L and Schneider, S and Bettio, G and Burian, M and Eckl-Dorna, J and Golet Fors, M and Marien, G and Morgenstern, C and Scheckenbach, K and Tomazic, P-V and Tu, A and Allu, S and Diamant, Z and Bachert, C and Isam Alobid Carlo Cavaliere Wytske Fokkens Peter W Hellings Claire Hopkins Adriana Izquierdo-Doming…, Chrinosor Consortium Isam Alobid Carlo Cavaliere Wytske Fok},
title = {Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR},
journal = {Rhinology Journal},
year = {2026},
doi = {10.4193/rhin25.514}
}
EUVIMED